The Foundation Board of Directors will meet on Monday December 19,2016 in Montreal.
ARSACS researchers will be at the Institute for Research in Immunology and Cancer at the University of Montreal (IRIC) on December 13, 2016 to analyze in greater details the first results of the drug screening therapeutic molecules carried out over the last months . Stay tuned.
Dr. Paul Chapple’s lab has successfully grown cells from a small biopsy of ARSACS patient skin and has reprogrammed them to become stem cells which can turn into other cell types. The following step was to grow ARSACS neurons from such stem cells. This resulted in obtaining ARSACS patient neurons in a petri dish available for research; a useful tool for modelling the disease. Image 3 shows some of these neurons, and in particular their long axonal process. See the following images: Image 1: ARSACS fibroblast, Image 2: iPSC colonies, Image 3: ARSACS derived neurons, Image 4: ARSACS fibroblasts mitochondria.
The Ataxia of Charlevoix-Saguenay Foundation and Ataxia UK are pleased to
announce a co-funding alliance to support and to advance medical research in the UK on ataxia
of Charlevoix-Saguenay. This alliance is clear evidence of openness and commitment towards ground-breaking research and future development in ataxias.
Care4Rare is a research project to identify therapeutic leads for rare diseases such as ARSACS. The Foundation is financing the ARSACS portion under the leadership of Dr. Kym Boycott and Dr. Alex MacKenzie from the Children Hospital of Eastern Ontario. Year 3 Progress Report
11 research projects will share $1 million as part of the Foundation’s research program for 2016-2017.